Eli Lilly said on Thursday it would appeal against a UK agency's recommendation to not reimburse the cost of Alzheimer's drug ...

Two breakthrough Alzheimer's drugs have been deemed far too expensive, for too little benefit, to be offered on the NHS. The ...

NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

Eli Lilly LLY signed a definitive agreement to acquire Verve Therapeutics VERV for a total deal value of nearly $1.3 billion.

Lilly Collaboration Accelerates RyboDyn's Dark Proteome Targets Toward First-in-Class Therapies SAN DIEGO, /PRNewswire/ -- RyboDyn, Inc., a biotechnology company pioneering first-in-class ...

A large, multicountry European study finds that adults with type 2 diabetes who start empagliflozin experience no increased ...

Scholar Rock's latest trial returned very positive results. Shares of Scholar Rock Holding (NASDAQ: SRRK) are soaring today, ...

Oprah Winfrey and Elon Musk endorsed it. And though Indian celebrities haven’t yet admitted to their use, the mystery ...

Mounjaro will soon be available on the NHS across the UK but it's important patients avoid the dangerous 'golden dose' trend ...

A huge surge in Ireland's goods exports in the first quarter of 2025 was partially due to demand for weight loss drugs in the ...

(Reuters) -A federal judge has rejected a bid by compounding pharmacies to allow them to continue making copies of Novo ...

However, in both cases, NICE immediately published draft guidance that concluded the anti-amyloid drugs were too expensive to ...